ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on Friday to close at $2.36 apiece after securing the green light of the European Medicines Agency (EMA) to sell its bladder cancer treatment Anktiva in Europe. In a statement, ImmunityBio Inc. (NASDAQ:IBRX) said that the EMA officially authorized Anktiva, in combination with Bacillus Calmette-Guerin (BCG), for th ...